Cite

HARVARD Citation

    Romano, A. et al. (2019). Immune off‐target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. British journal of haematology. pp. 468-479. [Online]. 
  
Back to record